Neurobo Pharmaceuticals Stock Fundamentals
| NRBO Stock | USD 2.37 0.02 0.85% |
Neurobo Pharmaceuticals fundamentals help investors to digest information that contributes to Neurobo Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Neurobo Stock. The fundamental analysis module provides a way to measure Neurobo Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurobo Pharmaceuticals stock.
At this time, Neurobo Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 25th of November 2024, Other Operating Expenses is likely to grow to about 18.8 M, while Depreciation And Amortization is likely to drop 5,700. Neurobo | Select Account or Indicator |
Neurobo Pharmaceuticals Company Return On Equity Analysis
Neurobo Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Neurobo Pharmaceuticals Return On Equity | -1.61 |
Most of Neurobo Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurobo Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Neurobo Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Neurobo Pharmaceuticals has a Return On Equity of -1.6076. This is 93.29% lower than that of the Biotechnology sector and 95.59% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Neurobo Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neurobo Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Neurobo Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neurobo Pharmaceuticals competition to find correlations between indicators driving Neurobo Pharmaceuticals's intrinsic value. More Info.Neurobo Pharmaceuticals is regarded third in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Neurobo Pharmaceuticals' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neurobo Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Neurobo Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurobo Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurobo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Neurobo Pharmaceuticals by comparing valuation metrics of similar companies.Neurobo Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Neurobo Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Neurobo Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Neurobo Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Neurobo Fundamentals
| Return On Equity | -1.61 | ||||
| Return On Asset | -0.74 | ||||
| Current Valuation | (1.1 M) | ||||
| Shares Outstanding | 8.62 M | ||||
| Shares Owned By Insiders | 65.23 % | ||||
| Shares Owned By Institutions | 12.71 % | ||||
| Number Of Shares Shorted | 19.2 K | ||||
| Price To Earning | (1.44) X | ||||
| Price To Book | 1.58 X | ||||
| Revenue | 7 K | ||||
| EBITDA | (15.88 M) | ||||
| Net Income | (12.47 M) | ||||
| Cash And Equivalents | 8.85 M | ||||
| Cash Per Share | 9.96 X | ||||
| Total Debt | 203 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.07 X | ||||
| Book Value Per Share | 1.50 X | ||||
| Cash Flow From Operations | (10.8 M) | ||||
| Short Ratio | 0.38 X | ||||
| Earnings Per Share | (4.29) X | ||||
| Target Price | 26.67 | ||||
| Beta | -0.28 | ||||
| Market Capitalization | 20.42 M | ||||
| Total Asset | 22.78 M | ||||
| Retained Earnings | (108.27 M) | ||||
| Working Capital | 16.55 M | ||||
| Current Asset | 21.62 M | ||||
| Current Liabilities | 11.75 M | ||||
| Net Asset | 22.78 M |
About Neurobo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurobo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 4.9 M | 5.1 M | |
| Total Revenue | 7 K | 7.3 K | |
| Cost Of Revenue | 7 K | 6.7 K |
Pair Trading with Neurobo Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurobo Stock
| 0.64 | ME | 23Andme Holding | PairCorr |
| 0.84 | VALN | Valneva SE ADR | PairCorr |
| 0.77 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Neurobo Stock
| 0.77 | KZR | Kezar Life Sciences | PairCorr |
| 0.53 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.37 | MDGL | Madrigal Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.
The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Neurobo Pharmaceuticals Piotroski F Score and Neurobo Pharmaceuticals Altman Z Score analysis. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Return On Assets (0.74) | Return On Equity (1.61) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.